IMVT vs TDG · $2.90B cap vs P/E 41, rev $8.83B
Immunovant Inc (IMVT) versus Transdigm Group Incorporated (TDG) — a side-by-side from cached financials, not a winner call.
Immunovant Inc (IMVT) is a biotechnology company listed on US.
Transdigm Group Incorporated (TDG) is a aerospace & defense company listed on NYSE.
IMVT does not have a complete income-statement cache yet.
Latest reported TDG revenue for 2025-09-30 was $8.83B. Net income was $2.07B. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
IMVT currently screens at market cap $2.90B. TDG currently screens at market cap $73.65B and trailing P/E 41.1.
Not investment advice. Open the IMVT and TDG stock pages for the full models.
Not investment advice.